Exploratory analyses from a trial of flotetuzumab, an investigational CD123 × CD3 bispecific dual-affinity retargeting antibody therapy, in AML demonstrated that TP53-mutated primary bone marrow samples exhibit greater CD8+ T-cell infiltration and inflammatory cytokine levels [92]. Here, TP53 is linked to acute myeloid leukemia.